AU2018234919A1 - Polymorphic compounds and uses thereof - Google Patents
Polymorphic compounds and uses thereof Download PDFInfo
- Publication number
- AU2018234919A1 AU2018234919A1 AU2018234919A AU2018234919A AU2018234919A1 AU 2018234919 A1 AU2018234919 A1 AU 2018234919A1 AU 2018234919 A AU2018234919 A AU 2018234919A AU 2018234919 A AU2018234919 A AU 2018234919A AU 2018234919 A1 AU2018234919 A1 AU 2018234919A1
- Authority
- AU
- Australia
- Prior art keywords
- compound
- salt
- present
- pct
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- GUHFUVLKYSQIOQ-UHFFFAOYSA-N CC(C)(c1nc(ccc(Cl)c2)c2cc1N)O Chemical compound CC(C)(c1nc(ccc(Cl)c2)c2cc1N)O GUHFUVLKYSQIOQ-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N Cc(cc1)ccc1S(O)(=O)=O Chemical compound Cc(cc1)ccc1S(O)(=O)=O JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N CC(C)(C(CC1)C2)C1(CS(O)(=O)=O)C2=O Chemical compound CC(C)(C(CC1)C2)C1(CS(O)(=O)=O)C2=O MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- LQBJOHIPPIVLCN-UHFFFAOYSA-N CC(Cc(cc1)ccc1S(O)(=O)=O)(c1nc(ccc(Cl)c2)c2cc1N)O Chemical compound CC(Cc(cc1)ccc1S(O)(=O)=O)(c1nc(ccc(Cl)c2)c2cc1N)O LQBJOHIPPIVLCN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/20—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/06—Oxalic acid
- C07C55/07—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472478P | 2017-03-16 | 2017-03-16 | |
| US62/472,478 | 2017-03-16 | ||
| US201762519331P | 2017-06-14 | 2017-06-14 | |
| US62/519,331 | 2017-06-14 | ||
| PCT/US2018/023000 WO2018170476A1 (fr) | 2017-03-16 | 2018-03-16 | Composés polymorphes et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2018234919A1 true AU2018234919A1 (en) | 2019-09-19 |
Family
ID=63521548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018234919A Abandoned AU2018234919A1 (en) | 2017-03-16 | 2018-03-16 | Polymorphic compounds and uses thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10414732B2 (fr) |
| EP (1) | EP3596040B1 (fr) |
| JP (2) | JP2020511461A (fr) |
| CN (1) | CN110431130A (fr) |
| AU (1) | AU2018234919A1 (fr) |
| CA (1) | CA3054811A1 (fr) |
| ES (1) | ES2968462T3 (fr) |
| IL (1) | IL268915A (fr) |
| MX (1) | MX2019010576A (fr) |
| WO (1) | WO2018170476A1 (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| JP6514114B2 (ja) | 2013-01-23 | 2019-05-15 | アルデイラ セラピューティクス， インコーポレイテッド | 毒性アルデヒド関連疾患および処置 |
| EP3337486B1 (fr) | 2015-08-21 | 2024-04-03 | Aldeyra Therapeutics, Inc. | Composés deutérés et leurs utilisations |
| AU2017224249A1 (en) | 2016-02-28 | 2018-09-13 | Aldeyra Therapeutics, Inc. | Treatment of allergic eye conditions with cyclodextrins |
| MX2018013472A (es) | 2016-05-09 | 2019-02-28 | Aldeyra Therapeutics Inc | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. |
| JP2020511461A (ja) | 2017-03-16 | 2020-04-16 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| WO2020033344A1 (fr) | 2018-08-06 | 2020-02-13 | Aldeyra Therapeutics, Inc. | Composés polymorphes et leurs utilisations |
| CA3113462A1 (fr) | 2018-09-25 | 2020-04-02 | Aldeyra Therapeutics, Inc. | Formulations pour le traitement de la maladie de l'~il sec |
| WO2020123730A1 (fr) | 2018-12-12 | 2020-06-18 | Teva Pharmaceuticals International Gmbh | Formes à l'état solide de reproxalap |
| JP2022526917A (ja) | 2019-03-26 | 2022-05-27 | アルデイラ セラピューティクス， インコーポレイテッド | 眼科用製剤およびその使用 |
| CN113784954A (zh) * | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| US20230149383A1 (en) * | 2020-04-13 | 2023-05-18 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2086186A (en) | 1933-10-10 | 1937-07-06 | Us Rubber Co | Treatment of rubber |
| GB1435721A (en) | 1972-05-18 | 1976-05-12 | Lilly Industries Ltd | Benzoxazole derivatives |
| SU509046A1 (ru) | 1975-02-21 | 1984-06-23 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Производные 2-карбэтокси-3-аминоиндола,про вл ющие противовоспалительную активность, и способ их получени |
| US4675332A (en) | 1984-12-10 | 1987-06-23 | Warner-Lambert Company | Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents |
| GB8610981D0 (en) | 1986-05-06 | 1986-06-11 | Ici America Inc | Quinoline amides |
| NZ225045A (en) | 1987-07-01 | 1990-06-26 | Janssen Pharmaceutica Nv | Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent |
| US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0506949A1 (fr) | 1990-10-22 | 1992-10-07 | BAUSCH & LOMB INCORPORATED | Procede et composition de nettoyage de verres de contact |
| CA2054339C (fr) | 1990-11-02 | 2002-12-24 | Francesco G. Salituro | Derives du 3-amidoindolyl |
| US5668117A (en) | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US5472954A (en) | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
| TW401300B (en) | 1992-12-25 | 2000-08-11 | Senju Pharma Co | Antiallergic composition for ophthalmic or nasal use |
| US5493027A (en) | 1993-01-22 | 1996-02-20 | Board Of Regents, The University Of Texas System | Anticonvulsive agents and uses thereof |
| US5767109A (en) | 1993-10-20 | 1998-06-16 | Sanchez; Robert A. | Complexing urushiols |
| US5576311A (en) | 1994-11-30 | 1996-11-19 | Pharmos Corporation | Cyclodextrins as suspending agents for pharmaceutical suspensions |
| JP3297969B2 (ja) | 1994-12-26 | 2002-07-02 | ライオン株式会社 | 点眼剤 |
| US5597823A (en) | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
| JP3736916B2 (ja) | 1996-02-19 | 2006-01-18 | 株式会社サンコンタクトレンズ | 含水性ソフトコンタクトレンズの消毒用組成物とその用途 |
| JP2001508029A (ja) | 1996-08-01 | 2001-06-19 | ダウ・アグロサイエンス・エル・エル・シー | 殺菌・殺カビ活性を有する４―置換キノリン誘導体 |
| DE59813690D1 (de) | 1997-05-02 | 2006-09-28 | Schering Ag | Substituierte heterocyclen und deren verwendung in arzneimitteln |
| GB2327672A (en) | 1997-07-23 | 1999-02-03 | Merck & Co Inc | 4-(1,2,3,4-Tetrahydro-1,8-naphthyridin-7-yl)butanoyl-glycyl-3(S)-quinolin-3-yl-beta-alanine |
| WO1999046237A1 (fr) | 1998-03-12 | 1999-09-16 | Novo Nordisk A/S | Modulateurs de proteine-tyrosine-phosphatases |
| US6358948B1 (en) | 1999-05-04 | 2002-03-19 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| US6498154B1 (en) | 1999-05-04 | 2002-12-24 | Wyeth | Cyclic regimens using quinazolinone and benzoxazine derivatives |
| WO2001035958A1 (fr) * | 1999-11-15 | 2001-05-25 | Smithkline Beecham Corporation | Methane-sulfonate de carvedilol |
| AU1735001A (en) | 1999-12-10 | 2001-06-18 | Senju Pharmaceutical Co., Ltd. | Cyclodextrin-containing pharmaceutical composition |
| US6569879B2 (en) | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
| JP4748289B2 (ja) | 2000-06-23 | 2011-08-17 | ライオン株式会社 | 点眼剤、眼科用組成物及び吸着抑制方法 |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| UA83620C2 (ru) | 2001-12-05 | 2008-08-11 | Уайт | Замещенные бензоксазолы и их аналоги как эстрогенные агенты |
| US20060014786A1 (en) | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| CA2451267A1 (fr) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Utilisations pharmaceutiques de ligands alpha2delta |
| US20040198828A1 (en) | 2003-01-17 | 2004-10-07 | Abelson Mark B. | Combinational use of long-acting and short-acting anti-histamines for ocular allergies |
| AU2004222279B2 (en) | 2003-03-14 | 2010-01-21 | University Of Washington | Retinoid replacements and opsin agonists and methods for the use thereof |
| US20060111318A1 (en) | 2003-04-18 | 2006-05-25 | Advanced Medicine Research Institute | Agent for treating eye diseases |
| EP2292239A3 (fr) | 2003-04-18 | 2011-03-30 | Advanced Medicine Research Institute | Remèdes à des affections, à usage ophtalmique |
| US7297709B2 (en) | 2003-05-22 | 2007-11-20 | Abbott Laboratories | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors |
| US20040235892A1 (en) | 2003-05-22 | 2004-11-25 | Yujia Dai | Indazole and benzisoxazole kinase inhibitors |
| US7083803B2 (en) | 2003-09-19 | 2006-08-01 | Advanced Ocular Systems Limited | Ocular solutions |
| KR101163800B1 (ko) | 2003-10-15 | 2012-07-09 | 산텐 세이야꾸 가부시키가이샤 | 신규 인다졸 유도체 |
| RU2006118325A (ru) | 2003-10-27 | 2007-12-10 | Астеллас Фарма Инк. (Jp) | Производные пиразина и их фармацевтическое применение |
| CN100558360C (zh) | 2003-11-20 | 2009-11-11 | 奥特拉控股公司 | 羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途 |
| US20050197292A1 (en) | 2004-01-30 | 2005-09-08 | Glennda Smithson | Compositions and methods for treating T-cell mediated pathological conditions |
| RU2006133300A (ru) | 2004-02-17 | 2008-03-27 | Президент Энд Феллоуз Оф Гарвард Колледж (Us) | Управление течением офтальмологических расстройств, включая дегенерацию желтого пятна |
| US20050234018A1 (en) | 2004-04-15 | 2005-10-20 | Allergan, Inc. | Drug delivery to the back of the eye |
| WO2006002473A1 (fr) | 2004-07-02 | 2006-01-12 | Adelaide Research & Innovation Pty Ltd | Procédé de controle de dommages causés par des aldéhydes alpha, béta-insaturés |
| JP2008518913A (ja) | 2004-10-28 | 2008-06-05 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体のピリミジン及びキノリン増強因子 |
| JPWO2006077821A1 (ja) | 2005-01-19 | 2008-06-19 | 大日本住友製薬株式会社 | アルドステロン受容体調節剤としての芳香族スルホン化合物 |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| JP4466875B2 (ja) | 2006-04-05 | 2010-05-26 | ライオン株式会社 | ソフトコンタクトレンズ用点眼剤 |
| CN101987849B (zh) | 2006-04-14 | 2013-05-08 | 普拉纳生物技术有限公司 | 治疗与年龄相关的黄斑变性(amd)的方法 |
| JP5194218B2 (ja) | 2006-06-05 | 2013-05-08 | 株式会社メニコンネクト | 含水性コンタクトレンズの保存方法ならびに該保存方法により保存された含水性コンタクトレンズ |
| JP2009544631A (ja) | 2006-07-25 | 2009-12-17 | エンビボ ファーマシューティカルズ インコーポレイテッド | キノリン誘導体 |
| US8158609B1 (en) | 2006-11-02 | 2012-04-17 | Novartis Ag | Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen |
| TW201242961A (en) | 2007-06-20 | 2012-11-01 | Ironwood Pharmaceuticals Inc | FAAH inhibitors |
| ES2615389T3 (es) | 2007-10-05 | 2017-06-06 | Acucela, Inc. | Alcoxifenilpropilaminas para el tratamiento de la degeneración macular relacionada con la edad |
| CA2714530C (fr) | 2008-02-11 | 2018-09-25 | University Of Washington | Procedes pour le traitement et la prevention d'un dysfonctionnement retinien lie a l'age |
| JP2012500202A (ja) | 2008-08-12 | 2012-01-05 | サートリス ファーマシューティカルズ， インコーポレイテッド | サーチュインモジュレーターとしてのベンゾオキサゾール、ベンズチアゾールおよび関連するアナログ |
| CA2754996A1 (fr) | 2009-03-17 | 2010-09-23 | Aciex Therapeutics, Inc. | Formulations ophtalmiques de ketotifene et procedes d'utilisation |
| WO2010133672A1 (fr) | 2009-05-20 | 2010-11-25 | Clanotech Ab | Dérivés d'acide quinoléine-3-carboxylique et leur utilisation médicale |
| WO2010148351A1 (fr) | 2009-06-18 | 2010-12-23 | Cylene Pharmaceuticals, Inc. | Rhodanines et hétérocycles associés en tant qu'inhibiteurs de kinase |
| WO2011008202A1 (fr) | 2009-07-15 | 2011-01-20 | Vanderbilt University | Piégeurs disokétal et réduction des troubles impliquant une lésion oxydative |
| CA2783699C (fr) | 2009-12-08 | 2019-01-15 | Case Western Reserve University | Composes d'amines primaires destines au traitement de troubles oculaires |
| CA2782015C (fr) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Compositions ophthalmiques topiques et methodes de traitement de la degenerescence maculaire |
| WO2011078204A1 (fr) | 2009-12-24 | 2011-06-30 | 浜理薬品工業株式会社 | Agent prophylactique ou thérapeutique destiné à une hyperlipémie et agent anti-fatigue |
| WO2011116066A1 (fr) | 2010-03-17 | 2011-09-22 | Concert Pharmaceuticals, Inc. | Dérivés de diméthylcurcumine |
| EP2663550B1 (fr) | 2011-01-12 | 2016-12-14 | VentiRx Pharmaceuticals, Inc. | Benzoazépines substituées utilisables comme modulateurs des récepteurs de type toll |
| WO2012100142A2 (fr) | 2011-01-20 | 2012-07-26 | Cornell University | Traitements de troubles rétiniens |
| CN103442735B (zh) | 2011-01-31 | 2016-11-09 | 特米拉公司 | 用于减轻技术领域中所不希望的医学状况的有效要素 |
| TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物 |
| US20130190500A1 (en) | 2011-12-12 | 2013-07-25 | Neuron Systems, Inc. | Process to prepare 6-chloro-3-amino-2-(2-hydroxypropyl)-1-azanaphthalene |
| US20130165419A1 (en) | 2011-12-21 | 2013-06-27 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
| WO2014022577A1 (fr) | 2012-08-01 | 2014-02-06 | Lewis And Clark Pharmaceuticals, Inc. | Utilisation de n-alkyl-2-(disubstitué)alkynyladénosine-5-uronamides comme agonistes du récepteur a2a |
| US20150258120A1 (en) | 2012-11-08 | 2015-09-17 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| JP2016503797A (ja) | 2012-12-20 | 2016-02-08 | アルデイラ セラピューティクス， インコーポレイテッド | ペリ−カルビノール |
| JP6514114B2 (ja) | 2013-01-23 | 2019-05-15 | アルデイラ セラピューティクス， インコーポレイテッド | 毒性アルデヒド関連疾患および処置 |
| SG11201505599YA (en) | 2013-01-25 | 2015-08-28 | Aldeyra Therapeutics Inc | Novel traps in the treatment of macular degeneration |
| US9713330B1 (en) | 2013-03-15 | 2017-07-25 | Deuteria Agrochemicals, Llc | Deuterium-enriched aldehydes |
| US10272106B2 (en) | 2014-06-04 | 2019-04-30 | Case Western Reserve University | Compositions and methods of treating diabetic retinopathy |
| NO2721710T3 (fr) | 2014-08-21 | 2018-03-31 | ||
| WO2016036674A1 (fr) | 2014-09-02 | 2016-03-10 | Bhupinder Singh | Molécule deutérée ou non-deutérée et formulations pharmaceutiques |
| WO2016085939A2 (fr) | 2014-11-24 | 2016-06-02 | Case Western Reserve University | Composés et méthodes de traitement de troubles oculaires |
| KR20180073553A (ko) * | 2015-08-21 | 2018-07-02 | 알데이라 테라퓨틱스, 아이엔씨. | 알데히드 접합체 및 이의 용도 |
| EP3337486B1 (fr) | 2015-08-21 | 2024-04-03 | Aldeyra Therapeutics, Inc. | Composés deutérés et leurs utilisations |
| AU2017224249A1 (en) | 2016-02-28 | 2018-09-13 | Aldeyra Therapeutics, Inc. | Treatment of allergic eye conditions with cyclodextrins |
| MX2018013472A (es) | 2016-05-09 | 2019-02-28 | Aldeyra Therapeutics Inc | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. |
| AU2017317529A1 (en) | 2016-08-22 | 2019-02-21 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and methods of use thereof |
| AU2017317524A1 (en) | 2016-08-22 | 2019-02-21 | Aldeyra Therapeutics, Inc. | Aldehyde trapping compounds and uses thereof |
| JP2020511461A (ja) | 2017-03-16 | 2020-04-16 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
-
2018
- 2018-03-16 JP JP2019550247A patent/JP2020511461A/ja active Pending
- 2018-03-16 WO PCT/US2018/023000 patent/WO2018170476A1/fr active Application Filing
- 2018-03-16 AU AU2018234919A patent/AU2018234919A1/en not_active Abandoned
- 2018-03-16 CA CA3054811A patent/CA3054811A1/fr not_active Abandoned
- 2018-03-16 MX MX2019010576A patent/MX2019010576A/es unknown
- 2018-03-16 EP EP18767183.9A patent/EP3596040B1/fr active Active
- 2018-03-16 CN CN201880018663.2A patent/CN110431130A/zh active Pending
- 2018-03-16 ES ES18767183T patent/ES2968462T3/es active Active
- 2018-03-16 US US15/924,005 patent/US10414732B2/en active Active
-
2019
- 2019-08-26 IL IL26891519A patent/IL268915A/en unknown
-
2023
- 2023-01-16 JP JP2023004641A patent/JP2023033426A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL268915A (en) | 2019-10-31 |
| WO2018170476A1 (fr) | 2018-09-20 |
| JP2023033426A (ja) | 2023-03-10 |
| US10414732B2 (en) | 2019-09-17 |
| MX2019010576A (es) | 2019-10-07 |
| US20180265474A1 (en) | 2018-09-20 |
| CA3054811A1 (fr) | 2018-09-20 |
| JP2020511461A (ja) | 2020-04-16 |
| EP3596040A1 (fr) | 2020-01-22 |
| CN110431130A (zh) | 2019-11-08 |
| EP3596040A4 (fr) | 2020-12-16 |
| ES2968462T3 (es) | 2024-05-09 |
| EP3596040B1 (fr) | 2023-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3596040B1 (fr) | Composés polymorphes de sels de 6-chloro-3-amino-2(2-hydroxypropyl)quinoline et leurs utilisations | |
| JP7332186B2 (ja) | アルデヒドコンジュゲートおよびその使用 | |
| US20210393612A1 (en) | Polymorphic compounds and uses thereof | |
| US11312692B1 (en) | Polymorphic compounds and uses thereof | |
| JP7179015B2 (ja) | Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用 | |
| JP2019532029A (ja) | アルデヒド補足化合物およびその使用 | |
| KR20180073554A (ko) | 중수소화 화합물 및 이의 용도 | |
| WO2016109470A1 (fr) | Stimulateurs à petites molécules des protéines co-activatrices des récepteurs de stéroïdes et méthodes pour les utiliser | |
| JP7218306B2 (ja) | 神経変性疾患を治療するための組成物 | |
| JP2022513030A (ja) | ヒストン脱アセチル化酵素６阻害剤を含む薬学的組成物 | |
| US10987367B2 (en) | Drug targets of delayed aging and human brain diseases | |
| TW201625264A (zh) | 水晶體硬化抑制劑 | |
| US20210196732A1 (en) | Drug Targets of Delayed Aging and Human Brain Diseases | |
| JP2023532134A (ja) | 網膜変性の処置において使用するための環式化合物 | |
| WO2014206877A1 (fr) | Composés médicamenteux à cibles multiples pour le traitement de troubles neurodégénératifs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |